Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 67 Cash-to-Debt is 12.96 as of Jun. 2026, which is 31% above its 10-year median of 9.90. GuruFocus rates THOXF with a GF Score™ of 67/100 and a GF Value™ of $0.15. The stock has 2 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Bioporto AS ranks better than 84.62% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bioporto AS's cash to debt ratio for the quarter that ended in Jun. 2026 was 12.96.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bioporto AScould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Bioporto AS's Cash-to-Debt or its related term are showing as below:
THOXF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.17 Med: 9.9 Max: No Debt
Current: 12.76
During the past 13 years, Bioporto AS's highest Cash to Debt Ratio was No Debt. The lowest was 3.17. And the median was 9.90.
THOXF's Cash-to-Debt is ranked better than 84.62% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs THOXF: 12.76
Bioporto AS (OTCPK:THOXF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Bioporto AS Cash-to-Debt Related Terms
Bioporto AS Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, Bioporto AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a Cash-to-Debt of 12.96 as of Jun. 2026. This is 31% above median its historical median of 9.90. Over the past decade, Bioporto AS's Cash-to-Debt has ranged from 3.17 to 10,000.00. According to the industry distribution chart, Bioporto AS ranks #32 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 15.4%.
Is Bioporto AS's Cash-to-Debt too high?
Bioporto AS's current Cash-to-Debt of 12.96 is 31% above median its 10-year median of 9.90. Over the past 10 years, this metric has ranged from a low of 3.17 to a high of 10,000.00. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. Bioporto AS's value of 12.96 is 1222.4% above this industry median. Based on the distribution chart, Bioporto AS ranks #32 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bioporto AS has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #32 out of 208 companies for Cash-to-Debt. This places Bioporto AS in the top 15% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. Bioporto AS's value of 12.96 is 1222.4% above this benchmark. Historically, Bioporto AS's own Cash-to-Debt has ranged from 3.17 to 10,000.00 over the past decade. While the company's 10-year median is 9.90 vs. the industry median of 0.98, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Cash-to-Debt of 12.96 is 1222.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Cash-to-Debt is 12.96, which is 31% above median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Cash-to-Debt of 12.96. The stock's GF Value™ is $0.15, compared to a current price of $0.15 — trading 0.7% below its estimated fair value. The current Cash-to-Debt is 12.96, which is 31% above median its 10-year median of 9.90 and 1222.4% above the Medical Diagnostics & Research industry median of 0.98. Bioporto AS's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Cash-to-Debt is 12.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 0.7% below its estimated GF Value™ of $0.15.
Key valuation signals for THOXF:
Cash-to-Debt: 12.96 (31% above median its 10-year median of 9.90)
GF Value™: $0.15 vs. price of $0.15 (0.7% below fair value)
Industry Position: 1222.4% above the Medical Diagnostics & Research median (#32 of 208)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
67GF Score
Get the complete analysis for THOXF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
